Browse All

Current Filters

CLEAR FILTER x

TITLE

Ublituximab, a Novel, Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), Demonstrates Enhanced Antibody-Dependent Cellular Cytotoxicity (ADCC) Relative to Other Anti-CD20 mAbs

Comparison of Strategies to Address Hypogammaglobulinemia Secondary to B-cell Depleting Therapies in Neuroimmunology Patients

Safety of the Concurrent Administration of Serotonergic Antidepressants and Ozanimod in Patients With Relapsing Multiple Sclerosis

Author:Naismith, Robert T.   Cohen, Jeffrey A.   Bar-Or, Amit   Comi, Giancarlo   Selmaj, Krzysztof W.   Hartung, Hans-Peter   Sheffield, James K.   Krakovich, Anthony   Cheng, Chun-Yen   Reardon, Jennifer   Riolo, Jon V.   Silva, Diego   Cree, Bruce A. C.   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.013  

Author Institution:Washington University School of MedicineWashington University School of Medicine, St Louis, Missouri, St Louis, MO  Mellen Center for MS Treatment and Research, Cleveland Clinic, Cleveland, Ohio, Cleveland, OH  Center for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of PennsylvaniaCenter for Neuroinflammation and Experimental Therapeutics, and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelph  Vita-Salute San Raffaele University and Casa di Cura del Policlinico, Milan, Italy, Milan, Italy  Center for Neurology, Lódz, Poland and Collegium Medicum, Department of Neurology, University of Warmia and Mazury, Olsztyn, Poland, Olsztyn, Poland  Department of Neurology, Medical Faculty, Heinrich-Heine University, Düsseldorf Germany  Brain and Mind Centre, University of Sydney, Australia  Department of Neurology, Medical University of Vienna, Austria  and Palacký University Olomouc, Olomouc, Czech Republic, Olomouc, Germany  Bristol Myers Squibb, Princeton, New Jersey, Princeton, PA  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Weill Institute for Neurosciences, Department of Neurology, University of California San FranciscoWeill Institute for Neurosciences, Department of Neurology, University of California San Francisco, San Francisco, California, San Francisco, CA  

Trends and Predictors of Peripheral CD19+ B-cell Repopulation in Patients Treated with Ocrelizumab during COVID-19 Pandemic

Remibrutinib: A Novel BTKi in Development for MS With a Favorable Safety Profile in Various Autoimmune Disorders

Author:Williams, Mitzi   Airas, Laura   Chitnis, Tanuja   Saini, Sarbjit   Hide, Michihiro   Sussman, Gordon   Nakahara, Jin   Bermel, Robert   Dörner, Thomas   Loop, Brett   Ziehn, Marina   Willi, Roman   Kieseier, Bernd C.   Nikolaev, Ivan   Haemmerle, Sibylle   Zharkov, Artem   Siegel, Richard   Cenni, Bruno   Wiendl, Heinz   Maurer, Marcus   Giménez-Arnau, Ana   Montalban, Xavier   

Session Name:P7: MS Therapeutics 1  

Topic:MS and Inflammatory Disease  

Program Number:P7.015  

Author Institution:Joi Life Wellness Group, Atlanta, GA, USA, Atlanta, GA  Turku University Hospital and University, Finland, Turku, Finland  Brigham and Women's Hospital, Department of Neurology, Boston, MA, USA, Boston, MA  Johns Hopkins Asthma and Allergy Center, Baltimore, MD, USA, Baltimore, MD  Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan, Hiroshima, Japan  University of Toronto, Toronto, Ontario, Canada, Toronto, ON, Canada  Department of Neurology, Keio University School of Medicine, Tokyo, Japan, Shinjuku-ku, Japan  Mellen Center for MS, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Department of Rheumatology and Clinical Immunology, Charite Universitätsmedizin Berlin  DRFZ, Berlin, Germany, Berlin, Germany  Novartis Pharmaceutical Corporation, Cambridge, MA, USA, Cambridge, MA  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Novartis Pharma AG, Basel, Switzerland  Department of Neurology, Heinrich-Heine University, Duesseldorf, Germany, Duesseldorf, Germany  Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland  Department of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany, Muenster, Germany  Urticaria Center of Reference and Excellence (UCARE), Institute of Allergology, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany  Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Allergology and Immunology, Berlin, Germany, Berlin, Germany  Department of Dermatology, Hospital del Mar - IMIM, Universitat Pompeu Fabra, Barcelona, Spain, Barcelona, Spain  Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain, Barcelona, Spain